Symbol(s): BKIT
Action

Downgrade

Recommendation

Buy

Timeframe

Short-Term

Risk

Medium

Blake Insomnia Sees A Big Opportunity In Helping Americans Sleep Better

January 23, 2019

/

05:41 AM PST

Source: CDC

This lack of sleep isn’t just a problem for employers, it is a problem for the health of the employees. A lack of sleep has been linked to all of the following :

– cause of accidents

– heart disease

– heart attack

– heart failure

– high blood pressure

– stroke

– diabetes

– lack of sex drive

– depression

– ages your skin

– weight gain

To try and alleviate insomnia people turn to sleep medications. The most common type of these are branded hypnotics such as Lunesta, Ambien and Rozerem. These medications work by numbing your alertness and forcing you to sleep.

They work, but the come with the very undesirable side effect of residual daytime grogginess/sedation. That circles us back to the loss of worker productivity that is plaguing American business.

Worse still the FDA has issued concerns about these branded hypnotics listing violent outbursts, hallucinations, binge eating and sleepwalking.

Despite being less than ideal, these branded hypnotic drugs generate a massive amount of revenue. In 2015 these medications combined for over $2 billion in sales.

That means there is a big opportunity for any company that can come up with a solution to insomnia that doesn’t bring with it the daytime sedation complication that these medications do.

That is what a tiny company called Blake Insomnia (BKIT) is trying to do. Blake Insomnia has a potentially groundbreaking insomnia drug called Zleepax. Zleepax seeks to help people get to sleep without creating any day after issues.

Join our community to participate in comments, rate stocks, receive daily updates, and more.
?

Leave a Reply

Your email address will not be published. Required fields are marked *